InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,048.42
(
0.00%
)
US TECH 100
17,148.36
(
1.00%
)
Dow Jones
38,085.80
(
0.00%
)
Brent Oil
88.55
(
0.45%
)
Bitcoin
64,380.33
(
-0.16%
)
Post# of 524
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

rusty8350

Send PM Follow Ignore
Followers 143
Posts 3888
Boards Moderated 2
Alias Born 06/13/2013

rusty8350

Re: Mithrandir67 post# 331

Friday, 10/03/2014 7:40:14 AM

Friday, October 03, 2014 7:40:14 AM

Post# of 524
On September 27, 2014, Endocyte, Inc. (the "Company") issued a press release announcing the interim update of overall survival analysis for the Phase 2b TARGET trial with investigational candidate vintafolide



My guess is the market doesn't mind this data. Although I looked through it and it seems to be positive apparently the powers to be must have been expecting better results?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up